Eton Pharmaceuticals, Inc. announced effective March 1, 2023, the company has appointed David Krempa to the position of chief business officer. Mr. Krempa previously was employed by the company in the Position of Senior Vice President, Business Development and Investor Relations. In connection with the appointment as chief business officer, Mr. Krempa will receive an annual salary of $385,000 and is eligible for an annual discretionary bonus as determined by the board of directors.

Mr. Krempa also participates in the company's 2018 Equity Incentive Plan along with other officers and employees of the company. Mr. Krempa's employment with the company is “at will” and his employment may be terminated by the company at any time for any reason or for no reason. In the event Mr. Krempa's employment is terminated without “cause” or he terminates his employment for “good reason,” he will receive six months' of his base salary as severance.

Further, if such termination occurs within twelve months of a change in control of the company, all of Mr. Krempa's unvested stock options shall immediately vest.